Eye Care Thought Leaders Join EyeGate Scientific Advisory Board
October 23 2017 - 8:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage, specialty pharmaceutical company
focused on developing and commercializing products using two
proprietary platform technologies for treating diseases and
disorders of the eye, has appointed two distinguished leaders in
the ophthalmic space, Vance Thompson, MD and Paul Karpecki, OD,
FAAO, to its scientific advisory board.
Barbara Wirostko M.D., Chief Medical Officer of EyeGate
commented, “We expect Dr. Thompson’s and Dr. Karpecki’s extensive
experience and vast knowledge of the cornea, dry eye, and anterior
segment to be invaluable as we continue progress in development of
our product candidates EyeGate OBG and EGP-437. We look forward to
working alongside these exceptionally talented individuals to
further the advancement of our pipeline.”
Dr. Karpecki is a prominent voice in optometry with over 20
years of experience. Currently he serves as Director of Cornea
Services for Kentucky Eye Institute in Lexington KY, The Ocular
Surface Disease Center at the Gaddie Eye Centers in Louisville KY
as well as an Associate Professor at the Kentucky College of
Optometry. In 2016, he was appointed as co-chair of the Tear Film
and Ocular Surface Society Symposium in Montpellier, France and
served as a member of the Diagnosis Sub-committee for TFOS DEWS
II.
He is also chief clinical editor and director of clinical
content for Review of Optometry, as well as chairman of the New
Technology and Treatment Conferences. He serves on the board for
the charitable organization Optometry Giving Sight and has
delivered over 1,000 lectures and authored over 1,000 papers.
Previously, he served as co-chair for the Dry Eye Summit, Director
for the CJO Optometric Dry Eye Guidelines for Eye Care.
Dr. Karpecki earned his doctor of optometry degree from Indiana
University. He completed a fellowship in medical cornea and
refractive surgery from the Pennsylvania College of Optometry. He
was one of two optometrists appointed to the Delphi International
Society at Wilmer-Johns Hopkins, which included the top 25 dry eye
experts in the world.
Dr. Vance Thompson is renowned globally for his thought
leadership in laser vision correction and advanced cataract
surgery. Currently, he is the Director of Refractive Surgery for
Vance Thompson Vision in Sioux Falls, Idaho and a Professor of
Ophthalmology at the Sanford USD School of Medicine. Dr. Thompson
has been instrumental in research and development of the most
advanced corneal and refractive technologies and techniques
associated with laser and implant vision correction. He has served
as the medical monitor lead or principal investigator in over 70
FDA monitored clinical trials studying laser and implant surgery.
Additionally, Dr. Thompson has lectured and published numerous
papers and book chapters on improvements in laser and intraocular
surgery, including being co-author of the textbook Refractive
Surgery.
Dr. Thompson received his BS in Chemistry and his MD degree from
the University of South Dakota. Following the accomplishment of his
ophthalmology residency at the University of Missouri/Columbia, he
completed a fellowship in Refractive and Cataract Surgery from
Hunkeler Eye Centers in Kansas City.
Eyegate's scientific advisory board is comprised of prominent
physicians and scientists who provide scientific and clinical
counsel on the advancement of the Company’s product pipeline. Other
members include Daniel Durrie, MD; C. Stephen Foster, MD; Randall J
Olson, MD; Jean-Marie Parel, PhD and Michael Raizman, MD.
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company
focused on developing and commercializing products using its two
proprietary platform technologies for treating diseases and
disorders of the eye.
EyeGate’s most advanced platform is based on a cross-linked
thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form
of the natural polymer hyaluronic acid (“HA”), which is a gel that
possesses unique physical and chemical properties such as hydrating
and healing when applied to the ocular surface. The ability of
CMHA-S to adhere longer to the ocular surface, resist degradation
and protect the ocular surface makes it well-suited for treating
various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials,
incorporates a reformulated topically active corticosteroid,
Dexamethasone Phosphate that is delivered into the ocular tissues
through EyeGate’s proprietary innovative drug delivery system, the
EyeGate II Delivery System. For more information, please
visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page
(https://www.facebook.com/ EyeGatePharma/), corporate Twitter
account (https://twitter.com/EyeGatePharma), and LinkedIn page
(https://www.linkedin.com/company/135892/) as channels of
distribution of information about EyeGate and its product
candidates. Such information may be deemed material information,
and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor EyeGate’s website and its social media accounts in addition
to following its press releases, SEC filings, public conference
calls, and webcasts. The social media channels that EyeGate
intends to use as a means of disclosing the information described
above may be updated from time to time as listed on EyeGate’s
investor relations website.
Forward-looking Statements
Some of the statements in this press release are
“forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product and those
of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate,
as well as the success thereof, with such approvals or success may
not be obtained or achieved on a timely basis or at all. These
statements involve risks and uncertainties that may cause results
to differ materially from the statements set forth in this press
release, including, among other things, certain risk factors
described under the heading “Risk Factors” contained in our Annual
Report on Form 10-K filed with the SEC on February 23, 2017 or
described in our other public filings. Our results may also be
affected by factors of which we are not currently aware. The
forward-looking statements in this press release speak only as of
the date of this press release. EyeGate expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is
based.
Contact:Lee Roth / Janhavi MohiteThe Ruth Group for EyeGate
Pharmaceuticals646-536-7012 / 7026lroth@theruthgroup.com /
jmohite@theruthgroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2023 to Apr 2024